Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

46.80 -0.75 (-1.58%)
Streaming Delayed Price Updated: 10:37 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
News headline image
3 Healthcare Stocks That Could Help Make You a Millionaire ↗
These stocks each have reached an important turning point that could signal growth ahead. 
Via The Motley Fool
News headline image
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich ↗
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
News headline image
2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years ↗
These businesses are exciting and can also lead to outsized long-term returns. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall? ↗
The benefits from its first drug launch will trickle in slowly, at least at first. 
Via The Motley Fool
News headline image
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗
These stocks could bring investors more than just a lump of coal for Christmas. 
Via The Motley Fool
News headline image
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip ↗
This biotech could have more winners on the way. 
Via The Motley Fool
News headline image
Where Will CRISPR Therapeutics Be in 5 Years? ↗
Does the recent approval make the stock a no-brainer buy? 
Via The Motley Fool
News headline image
After This Landmark Win, Is CRISPR Therapeutics a Buy? ↗
CRISPR Therapeutics stock already has advanced in the double digits this year. 
Via The Motley Fool
News headline image
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
News headline image
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030 ↗
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy. 
Via InvestorPlace
Topics ETFs
News headline image
Cathie Wood Just Dumped $40 Million of Coinbase Global (COIN) Stock ↗
Wood is moving away from fintech and Internet names like COIN stock. She's now favoring genomics and artificial intelligence companies. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
1 Biotech Stock That Could Be the Next Amgen ↗
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
News headline image
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? ↗
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now. 
Via The Motley Fool
News headline image
3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
News headline image
Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam ↗
 
Via Benzinga
News headline image
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine ↗
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
News headline image
Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗
Intellia is approaching the finish line. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails ↗
On Monday, Cathie Wood-led Ark Invest made a significant move by selling over $12.8 million worth of Grayscale Bitcoin Trust (OTC:GBTC) shares, amidst fluctuating cryptocurrency prices. 
Via Benzinga
News headline image
Why CRISPR Stock Keeps Falling ↗
CRISPR just scored its first FDA victory -- but profits remain years away. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
News headline image
HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Bull Of The Day: Crispr Therapeutics ↗
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
News headline image
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
News headline image
The 3 Best Cathie Wood Stocks to Buy in December ↗
Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop. 
Via InvestorPlace
News headline image
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? ↗
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
News headline image
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
News headline image
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review ↗
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
News headline image
Healthcare Gems: 3 Essential Long-Term Stock Picks ↗
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.